WO2001093889A3 - Vip-related peptides for the treatment of skin disorders - Google Patents

Vip-related peptides for the treatment of skin disorders Download PDF

Info

Publication number
WO2001093889A3
WO2001093889A3 PCT/IL2001/000523 IL0100523W WO0193889A3 WO 2001093889 A3 WO2001093889 A3 WO 2001093889A3 IL 0100523 W IL0100523 W IL 0100523W WO 0193889 A3 WO0193889 A3 WO 0193889A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
vip
skin disorders
present
skin
Prior art date
Application number
PCT/IL2001/000523
Other languages
French (fr)
Other versions
WO2001093889A2 (en
Inventor
Illana Gozes
Ruth Granoth
Matityahu Fridkin
E Douglas Brenneman
Original Assignee
Yeda Res & Dev
Univ Ramot
Us Gov Health & Human Serv
Illana Gozes
Ruth Granoth
Matityahu Fridkin
E Douglas Brenneman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Univ Ramot, Us Gov Health & Human Serv, Illana Gozes, Ruth Granoth, Matityahu Fridkin, E Douglas Brenneman filed Critical Yeda Res & Dev
Priority to EP01940960A priority Critical patent/EP1307217A2/en
Priority to AU2001274446A priority patent/AU2001274446A1/en
Publication of WO2001093889A2 publication Critical patent/WO2001093889A2/en
Publication of WO2001093889A3 publication Critical patent/WO2001093889A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to pharmaceutical compositions for the treatment of skin disorders comprising as active ingredient VIP-related peptides. It has been shown by the present invention that the compositions disclosed and claimed induce cell apoptosis and therefore may be used particularly for the treatment of skin disorders associated with hyperproliferation of skin cells. The present invention also provides a method for the treatment of hyperproliferative skin disorders and/or for inducing cell apoptosis, the method involving administration to the skin area to be treated a therapeutically effective amount of the VIP-related peptide.
PCT/IL2001/000523 2000-06-07 2001-06-07 Vip-related peptides for the treatment of skin disorders WO2001093889A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01940960A EP1307217A2 (en) 2000-06-07 2001-06-07 Vip-related peptides for the treatment of skin disorders
AU2001274446A AU2001274446A1 (en) 2000-06-07 2001-06-07 Vip-related peptides for the treatment of skin disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13663100A IL136631A0 (en) 2000-06-07 2000-06-07 Vip-related peptides for treatment of skin disordes
IL136631 2000-06-07

Publications (2)

Publication Number Publication Date
WO2001093889A2 WO2001093889A2 (en) 2001-12-13
WO2001093889A3 true WO2001093889A3 (en) 2003-02-27

Family

ID=11074239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000523 WO2001093889A2 (en) 2000-06-07 2001-06-07 Vip-related peptides for the treatment of skin disorders

Country Status (4)

Country Link
EP (1) EP1307217A2 (en)
AU (1) AU2001274446A1 (en)
IL (1) IL136631A0 (en)
WO (1) WO2001093889A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2313783A2 (en) * 2008-07-18 2011-04-27 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
EP3263125A3 (en) * 2011-02-02 2018-03-14 Emory University Antagonism of the vip signaling pathway

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540969A2 (en) * 1991-10-31 1993-05-12 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540969A2 (en) * 1991-10-31 1993-05-12 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRANOTH, RUTH ET AL: "Neuropeptides and skin cell function: VIP and stearyl-[Nle17]VIP effects on HaCaT cells", XP002211498, retrieved from STN Database accession no. 131:209404 *
PEPTIDES: FRONTIERS OF PEPTIDE SCIENCE, PROCEEDINGS OF THE AMERICAN PEPTIDE SYMPOSIUM, 15TH, NASHVILLE, JUNE 14-19, 1997 (1999), MEETING DATE 1997, 749-750. EDITOR(S): TAM, JAMES P.;KAUMAYA, PRAVIN T. P. PUBLISHER KLUWER, DORDRECHT, NETH. *
PINCELLI C ET AL: "SUBSTANCE P IS DIMINISHED AND VASOACTIVE INTESTINAL PEPTIDE IS AUGMENTED IN PSORIATIC LESIONS AND THESE PEPTIDES EXERT DISPARATE EFFECTS ON THE PROLIFERATION OF CULTURED HUMAN KERATINOCYTES", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 98, no. 4, 1992, pages 421 - 427, XP001098347, ISSN: 0022-202X *
RABIER MIREILLE J ET AL: "Neuropeptides modulate leukotriene B-4 mitogenicity toward cultured human keratinocytes.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 100, no. 2, 1993, pages 132 - 136, XP001098344, ISSN: 0022-202X *
WOLLINA UWE ET AL: "Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix.", REGULATORY PEPTIDES, vol. 70, no. 1, 1997, pages 29 - 36, XP002211497, ISSN: 0167-0115 *

Also Published As

Publication number Publication date
IL136631A0 (en) 2001-06-14
EP1307217A2 (en) 2003-05-07
WO2001093889A2 (en) 2001-12-13
AU2001274446A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2002043652A3 (en) Anti-proliferative drugs
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
WO2002066500A3 (en) ANTAGONISTS FPR Α4β7-INTEGRIN
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
WO2004047771A3 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
WO2005037347A3 (en) Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents
WO2002051379A3 (en) Thixotropic nasal spray
WO2005004854A3 (en) Use of betaine for treating arteritis
WO2002065989A3 (en) Aminoglycoside treatment for lysosomal storage diseases
DE60310742D1 (en) EXTRACT WITH ANTITUMORAL AND ANTITOXIC EFFECT
WO2006029487A3 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
WO2001093889A3 (en) Vip-related peptides for the treatment of skin disorders
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001940960

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001940960

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001940960

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP